Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Stryker is a global leader in orthopaedic products and medical device equipment. Operations are segmented into Orthopaedic Implants (reconstructive, trauma, spine, micro implants) and MedSurg Equipment (powered surgical instruments, endoscopy, patient handling). Domestic sales accounted for 64% of total revenue in the first half of 2005.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2005 |
|---|---|---|
| Net Sales | $1,218.6 | $2,421.1 |
| Gross Profit | $796.4 | $1,569.8 |
| Gross Margin | 65.4% | 64.8% |
| Operating Income | $261.6 | $507.8 |
| Net Earnings | $184.3 | $357.4 |
| Diluted EPS | $0.45 | $0.87 |
| Cash from Operations | $187.2 | $219.2 |
| Cash & Equivalents | $118.4 | $118.4 |
| Marketable Securities | $212.0 | $212.0 |
| Total Debt (Current + Long-Term) | $9.2 | $9.2 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% year-over-year for both the quarter and the six-month period. Growth was driven by a 12% increase in unit volume/mix, 2% from favorable foreign currency, 2% from price increases, and 1% from acquisitions.
- Profitability: Net earnings rose 21% for the quarter and 24% for the six-month period compared to 2004. Operating margins improved to 21.5% (Q2) and 21.0% (YTD) from 21.1% and 19.9% respectively in the prior year.
- Segment Performance:
- Orthopaedic Implants: Sales up 15% (Q2) and 14% (YTD). Strong growth in Trauma (21%), Spine (22%), and Knees (16%).
- MedSurg Equipment: Sales up 22% (Q2) and 23% (YTD). Driven by endoscopic products (27-29% growth) and patient handling equipment.
- Acquisition: Acquired eTrauma.com Corp. for approximately $50 million in cash in February 2005 to expand endoscopic and video imaging capabilities. Results included from acquisition date; did not materially impact reported results.
- Working Capital: Working capital increased by $190.6 million to $1,219.7 million. Days sales outstanding improved to 55 days from 58 days.
Guidance, Outlook, and Risks
- 2005 Outlook: Management expects diluted net earnings per share to approximate $1.75. Net sales growth is projected at 14% to 15%, driven by Orthopaedic and MedSurg growth and favorable currency impacts.
- Liquidity: The company has paid off substantially all borrowings under credit facilities. It holds $118.4 million in cash and $212.0 million in marketable securities. Additional borrowing capacity of $819.3 million remains available.
- Legal Contingencies:
- Cooperating with a Department of Justice investigation regarding billing practices of subsidiary Physiotherapy Associates (subpoenaed Dec 2003).
- Cooperating with a DOJ investigation regarding consulting contracts and remuneration agreements with orthopedic surgeons (subpoenaed March 2005).
- Accounting Changes: Plans to adopt FASB Statement No. 123(R) regarding stock-based compensation effective January 1, 2006. Pro forma impact for the six months ended June 30, 2005, would reduce net earnings by $12.9 million.
- Foreign Currency: Weakening foreign currencies reduced the value of international net assets by $147.5 million in the first half of 2005, recorded in accumulated other comprehensive gain.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 17% sales growth, specifically the contribution from unit volume versus price increases and foreign currency fluctuations.
- Legal Exposure: Monitor the status and potential financial impact of the two ongoing Department of Justice investigations.
- Acquisition Integration: Assess the integration progress and future revenue contribution of the eTrauma.com acquisition.
- Stock Compensation Impact: Review the impact of the upcoming adoption of FASB 123(R) on future reported earnings starting in 2006.
- Capital Allocation: Confirm the company's strategy for deploying excess cash, given the reduction in debt and significant cash reserves.